GE Healthcare Bio-Science AB

GE Healthcare Bio-Science AB has been granted 258 US utility patents between 2015 and 2024, placing GE Healthcare Bio-Science AB at rank #1,602 across all assignees tracked by PlainPatent. This portfolio spans 68 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.5 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, GE Healthcare Bio-Science AB is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 53.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 37 grants, compared with 221 in the 2015–2019 window — a -83% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. GE Healthcare Bio-Science AB's 14.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 68 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GE Healthcare Bio-Science AB against peers pursuing similar technology classes.